Managing reactivation of multiple sclerosis during treatment with natalizumab
This exploratory study indicates that switching to anti-CD20 therapies following natalizumab failure is associated with a >50% reduction in relapse risk. No differences were seen in secondary outcomes, despite consistent trends. Clinicians may consider anti-CD20 therapies following natalizumab failure, noting further research is needed to confirm differences in MRI and disability outcomes.
Authors
- Eduardo Agüera (ORCID: https://orcid.org/0000-0002-8604-2054)
- Murat Terzi (ORCID: https://orcid.org/0000-0002-3586-9115)
- Sifat Sharmin (ORCID: https://orcid.org/0000-0001-7294-9723)
- Guy Laureys (ORCID: https://orcid.org/0000-0002-1708-4373)
- Saloua Mrabet (ORCID: https://orcid.org/0000-0003-2718-1828)
- Nevin John (ORCID: https://orcid.org/0000-0002-9834-4498)
- Tomáš Kalinčík (ORCID: https://orcid.org/0000-0003-3778-1376)
- Dana Horáková (ORCID: https://orcid.org/0000-0003-1915-0036)
- Helmut Butzkueven (ORCID: https://orcid.org/0000-0003-3940-8727)
- María José Sá (ORCID: https://orcid.org/0000-0003-0825-2977)
- Bassem Yamout (ORCID: https://orcid.org/0000-0002-2540-6651)
- Anneke van der Walt (ORCID: https://orcid.org/0000-0002-4278-7003)
- Sara Eichau (ORCID: https://orcid.org/0000-0001-9159-3128)
- Jens Kühle (ORCID: https://orcid.org/0000-0002-6963-8892)
- Maria Pia Amato (ORCID: https://orcid.org/0000-0003-3325-3760)
- Cavit Boz (ORCID: https://orcid.org/0000-0003-0956-3304)
- Pierre Duquette (ORCID: https://orcid.org/0000-0001-7231-1754)
- Izanne Roos (ORCID: https://orcid.org/0000-0003-0371-3666)
- Nathaniel Lizak (ORCID: https://orcid.org/0009-0009-3213-8390)
- François Grand’Maison (ORCID: https://orcid.org/0000-0003-0091-0074)
- Samia Joseph Khoury (ORCID: https://orcid.org/0000-0003-3198-6063)
- Suzanne Hodgkinson (ORCID: https://orcid.org/0000-0002-9029-6663)
- Pierre Grammond (ORCID: https://orcid.org/0000-0001-6341-724X)
- Francesco Patti (ORCID: https://orcid.org/0000-0002-6923-0846)
- Alexandre Prat (ORCID: https://orcid.org/0000-0001-6188-0580)
- Abdullah Rashid Al-Asmi (ORCID: https://orcid.org/0000-0002-2851-8157)
- Riadh Gouider (ORCID: https://orcid.org/0000-0001-9615-3797)
- Eva Havrdová (ORCID: https://orcid.org/0000-0002-9543-4359)
- Tünde Csépány (ORCID: https://orcid.org/0000-0002-8305-3209)
- Raed Alroughani
- Marc Girard (ORCID: https://orcid.org/0000-0001-8207-8896)
- Elisabetta Cartechini
- Olga Skibina (ORCID: https://orcid.org/0009-0000-1542-5659)
- Oliver Gerlach
- Katherine Buzzard
- Jeannette Lechner-Scott
Institutions
- Tunis University (TN)
- The Royal Melbourne Hospital (AU)
- University of Debrecen (HU)
- Box Hill Hospital (AU)
- İzmir University of Economics (TR)
- Fernando Pessoa University (PT)
- Zuyd University of Applied Sciences (NL)
- Charles University (CZ)
- Ondokuz Mayıs University (TR)
- John Hunter Hospital (AU)
- Ghent University Hospital (BE)
- The Alfred Hospital (AU)
- University Hospital of Basel (CH)
- Amiri Hospital (KW)
- Hunter Medical Research Institute (AU)
- Hospital Universitario Virgen Macarena (ES)
- Instituto Maimónides de Investigación Biomédica de Córdoba (ES)
- Eastern Health (AU)
- American University of Beirut Medical Center (LB)
- Don Carlo Gnocchi Foundation (IT)
- Monash Health (AU)
- Policlinico Universitario di Catania (IT)
- Zuyderland Medisch Centrum (NL)
- Ingham Institute (AU)
- Centre intégré de santé et de services sociaux de Chaudière-Appalaches (CA)
- Farabi Hastanesi (TR)
- General University Hospital in Prague (CZ)
- Faculté de médecine de Tunis
- University of Florence (IT)
- Sultan Qaboos University (OM)
- University of Macerata (IT)
- Monash University (AU)
- Tunis El Manar University (TN)
- Université de Montréal (CA)
Publication Details
- Journal
- Multiple Sclerosis Journal
- Published
- 2025-12-19
- DOI
- https://doi.org/10.1177/13524585251398682
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- Celgene
- F. Hoffmann-La Roche
- Universität Basel
- Atara Biotherapeutics
- International Progressive MS Alliance
- Multiple Sclerosis Society of Canada
- European Commission
- Bayer HealthCare
- Multiple Sclerosis Australia
- National Research Foundation
- Monash University
- Eisai
- Università di Catania
- Multiple Sclerosis International Federation
- Trish Multiple Sclerosis Research Foundation
- EMD Serono
- Sanofi Genzyme
- Canadian Institutes of Health Research
- Medical Research Council
- National Health and Medical Research Council